Home/OCON Therapeutics/Keren Leshem

KL

Keren Leshem

Chief Executive Officer

OCON Therapeutics

Therapeutic Areas

Contraception Abnormal Uterine Bleeding Heavy Menstrual Bleeding Endometriosis Uterine Fibroids Infertility

OCON Therapeutics Pipeline

Drug	Indication	Phase
IUB® BALLERINE®	Hormone‑free contraception	Phase 2
IUB® SEAD®	Abnormal uterine bleeding / heavy menstrual bleeding	Phase 2
IUB® PRIMA®	Endometriosis, uterine fibroids, hormonal disorders	Pre‑clinical

Leadership Team at OCON Therapeutics

Chief Financial Officer & General Manager

Daniela Schardinger

VP Marketing & Medical Affairs

VP Regulatory Affairs / Quality Assurance

Susan Alpert, PhD, MD

Senior Regulatory Advisor

View full OCON Therapeutics profile